Current antiviral treatment course is inadequate for high-risk COVID-19

Molnupiravir's impact on SARS-CoV-2 response in at-risk outpatients.

Continue reading Current antiviral treatment course is inadequate for high-risk COVID-19 on Tech Explorist.

Share on Google Plus

About admin

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.